Magnafolate^® · Industry Insights

They're All 6S-5-Methyltetrahydrofolate Calcium—So How Different Can They Really Be?

A closer look at the C crystal form of Magnafolate^®

Publishing suggestion: Company website newsroom / WeChat official account / industry media (NutraIngredients-Asia, Phytochem Bridge, FBIF, etc.)

Target readers: R&D, procurement, and marketing leads at functional-food, health-food, and FSMP brand owners

More and more products on the market now carry the claim "contains 6S-5-MTHF."The CAS number is identical. The test reports all pass. Yet the prices can vary considerably.

Where does the difference come from? The crystal form.

Active folate—6S-5-Methyltetrahydrofolate calcium—has moved from an emerging ingredient to a clear direction for the folate market.As consumers have learned more about MTHFR gene polymorphisms, their questions have changed, too. They used to ask, "Do I need folate?" Now they ask, "Which form should I take?"Brands can’t avoid that question. Neither can their procurement teams.

The problem is that the folate raw-material market is crowded with imitators.Even when the ingredient is the same 6S-5-Methyltetrahydrofolate calcium, the C crystal form, I crystal form, and glucosamine salt can differ by several orders of magnitude in stability and in vivo utilization efficiency.The competitive focus is shifting—from "Does the product contain active folate?" to "Which crystal form of active folate does it contain?"

Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. is the world’s second company—and the only company in China—with an independent crystal form and a complete intellectual property portfolio for active folate.Using its proprietary "room-temperature ultrasonic interfacial" preparation process, the company developed the C crystal form. Related patents have been granted in China, the United States, Europe, Japan, South Korea, Canada, and India.Magnafolate® is the commercial name for this C crystal form.This article looks at the publicly available data behind it—and what that data can actually do for a brand when it becomes part of a product strategy.

01  From "The Same CAS Number" to Distinct Crystal Forms: It’s Time to Reconsider How Active Folate Quality Is Judged

The industry has traditionally evaluated folate raw materials based on a handful of physicochemical indicators: assay, purity, moisture, and heavy metals.Those metrics matter. But they are not enough.

A 2021 comparative study published in Molecules by Lian et al. made the distinction clear. Although all three materials were 6S-5-Methyltetrahydrofolate calcium, their degradation rates at room temperature were completely different:

t₀.₉—the time required for the assay to fall to 90%—was:

• 13.4 hours for the C crystal form

• 10.2 hours for the I crystal form

• Only 4.51 hours for the amorphous glucosamine salt

After 120 hours, the increase in 4-aminobenzoylglutamic acid impurities in the amorphous form was approximately 2.5 times that of the C crystal form.

Active folate is a sensitive ingredient. It is vulnerable to oxygen and moisture, and the race against time begins the moment it leaves the factory.Two crystal forms may show the same assay on their certificates of analysis. But after drying, packaging, storage, transportation, and tablet compression, the finished materials can tell two very different stories.

That means active folate quality needs to be assessed with a different yardstick:The question should not be limited to whether the material passed inspection on the day it left the factory. It should also ask whether the crystal structure is controlled and whether stability is maintained throughout the product’s entire life cycle.

Jinkang Hexin has a strong position on both fronts.Chinese invention patent CN104557937B protects the C-form crystal of (6S)-5-Methyltetrahydrofolate calcium and its ultrasound-assisted preparation method. Its claims extend to pharmaceutical active ingredients and food-additive applications.Family patents have also been granted in the United States (US9150982B2), Europe (EP2805952), Japan (JP6166736), South Korea (KR10-1694710), Canada (CA2861891), and India (IN342588).These patents protect the underlying structure of active folate quality—not merely the parameters of one particular production step.

There is another layer beyond the papers and patents.Jinkang Hexin led the development of China’s national food-safety standards for active folate and has driven five upgrades to those standards.The application range of C-crystal-form active folate now extends across 12 major categories, including formulated milk powder, foods for special medical purposes, wheat flour, and complementary food supplements.Brands understand the significance of this. A raw-material supplier’s participation in developing national standards can be a meaningful advantage during registration, regulatory filings, and compliance reviews.

02  351%: What Pharmacokinetic Data Tells Us

Stability is only the baseline.

What happens after the ingredient enters the body is the question brands really need to answer.

In the same study, researchers used LC-MS/MS to measure plasma concentrations in rats after oral administration of the three forms:

The relative bioavailability of the C crystal form was 351% of the I crystal form and 218% of the amorphous form.

Put into formulation language, these figures tell us three things.

At the same dosage, the AUC of the C crystal form was 3.5 times that of the I crystal form. The difference in the amount of effective folate reaching systemic circulation was substantial.

Its mean residence time was 3.7 times longer than that of the I crystal form. Plasma concentrations stayed elevated for longer, creating a broader exposure window.

There is also a hidden cost calculation.If a non-C crystal form is used, the dosage may need to be increased to achieve a comparable level of in vivo exposure. The raw-material price may look lower, but the economics can change once it is built into the full formulation.

For product positioning, this is a meaningful upgrade.One approach says: "Each tablet contains XXX mg of active folate."The other says: "Formulated with patented C-crystal-form raw material, with pharmacokinetic research demonstrating 3.5-fold higher relative bioavailability than the conventional crystal form."The first is a simple ingredient statement. The second is a documented product differentiator supported by published research.

03  Covering 78.4% of the Chinese Population: The Science Behind Precision Nutrition

The precision-nutrition story has to be grounded in population data.

A 2013 study published in PLoS ONE by Yang et al. analyzed 15,357 Chinese adults of Han nationality:

• 55.7% carried the CT heterozygous mutation, associated with reduced MTHFR enzyme activity.

• 26.4% carried the TT homozygous mutation, with folate-conversion efficiency at only about one-third that of the normal genotype.

• Taken together, approximately 78.4% of participants carried the T allele, indicating varying degrees of limitation in folate metabolism and conversion.

Calcium 6S-5-Methyltetrahydrofolate does not need to pass through the MTHFR enzyme pathway. It can be absorbed directly in the intestine.Those four words—"absorbed directly"—are central to the scientific rationale behind active folate. They also provide one of the strongest foundations for differentiated positioning in finished products.

Looking one step further, an animal study published in China Medical Herald in 2021 found that 30 consecutive days of oral administration of 6S-5-Methyltetrahydrofolate calcium increased NK-cell activity in mice from 3.44% in the control group to 14.35%–22.03% (P<0.01), suggesting research potential in immune regulation.The boundary needs to be clear: these are animal-study findings and cannot be directly extended to efficacy claims in humans. Product claims must remain within the requirements of food and health-food regulations.For brands planning future product pipelines, however, the findings offer a research direction worth monitoring.

04  Four Ways Magnafolate^® Creates Value for Brands

1. A stronger narrative asset

Brands that obtain formal supply and technical-marketing authorization for Magnafolate^® can include traceable technical points such as its "seven-country crystal-form patent family" and "351% relative bioavailability" in packaging, consumer education, and channel-development materials. Instead of simply saying "contains ingredient X," the brand can communicate data supported by patent numbers and published research.

2. More efficient ingredient selection

Crystal-form identification by XRD, stability data, and pharmacokinetic parameters provide an additional layer of evaluation beyond purity during the early stages of product development. That can shorten the research cycle and reduce the risk of formulation problems later on.

3. A more complete compliance package

Crystal-form characterization, stability studies, toxicology data, and pharmacokinetic literature are available as a complete package. These materials can support registration filings, compliance reviews for product claims, and raw-material traceability.

4. Greater confidence in international expansion

The C crystal form is an original invention by a Chinese company. Related patents have been granted in China, the United States, Europe, Japan, South Korea, Canada, and India, covering most of the world’s major nutrition-ingredient markets. For brands expanding overseas, this adds a layer of intellectual-property support that can be clearly documented with specific patent numbers in registration dossiers and distributor materials.

05  When Active Folate Is No Longer Scarce, What Becomes Scarce Is the Ability to Define High-Quality Active Folate

Competition in the folate raw-material industry is no longer simply about comparing assay and price.It is about crystal structure, stability data, and intellectual property.

Magnafolate^® brings all three together:A patent family granted in seven countries and regions; the status of its manufacturer as a participant in national standard development; traceable stability and pharmacokinetic data; and a population-based rationale covering 78.4% of Chinese adults.From sample verification to formulation implementation, technical support is available throughout the process.

Taking control of the quality standards for active folate—that is the path Magnafolate^® hopes to pursue together with its partners.

References

[1] Lian Z, Chen H, Liu K, et al. Improved Stability of a Stable Crystal Form C of 6S-5-Methyltetrahydrofolate Calcium Salt, Method Development and Validation of an LC–MS/MS Method for Rat Pharmacokinetic Comparison. Molecules, 2021, 26(19): 6011.

[2] Yang B, Liu Y, Li Y, et al. Geographical Distribution of MTHFR C677T, A1298C and MTRR A66G Gene Polymorphisms in China: Findings from 15,357 Adults of Han Nationality. PLoS ONE, 2013, 8(3): e57917.

[3] Xue J, Ma W, Tu H, et al. Study on the Immune-Enhancing Effects of 6S-5-Methyltetrahydrofolate Calcium in Mice. China Medical Herald, 2021, 11(17): 29–33.

[4] Lian Z, Liu K, Gu J, et al. Biological Characteristics and Applications of Folate and 5-Methyltetrahydrofolate. China Food Additives, 2022(2): 229–238.

[5] Wang Z, Cheng Y, Huang H, et al. Crystal Form of (6S)-5-Methyltetrahydrofolate Salt and Method for Preparing Same. U.S. Patent 9150982 B2, 2015.

[6] Wang Zheqing, Cheng Yongzhi, Huang Heng. Crystal Form of (6S)-5-Methyltetrahydrofolate Salt and Method for Preparing Same. Chinese Invention Patent CN104557937B, granted March 8, 2017.

[7] Granted family patents: Europe EP2805952; Japan JP6166736; South Korea KR10-1694710; Canada CA2861891; India IN342588.

About the Company

Established in 2007, Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. is a high-tech company focused on Naturalization folate—6S-5-Methyltetrahydrofolate calcium—as its core business. It is the world’s second company, and the only company in China, with an independent crystal form and a complete intellectual property portfolio for active folate.

Facing decades of technological dominance by Merck in the active-folate sector, the company spent three years developing a breakthrough solution. It created the world’s first "room-temperature ultrasonic interfacial" preparation process and successfully developed C-crystal-form active folate with higher purity and improved stability.The product, Magnafolate^®, has reached a practically non-toxic safety level. It offers advantages including no need for metabolic conversion, direct absorption, and no masking of vitamin B12 deficiency. It also has significant application value in areas such as the prevention of birth defects and cardiovascular health.

Built on its core technological innovations, the company has established a patent portfolio covering major global markets, including China, the United States, Europe, Japan, and South Korea. It holds more than 40 granted invention patents worldwide.The company has also been recognized as a National High-Tech Enterprise and a Jiangsu Province Specialized, Specialized, and New SME. It led the development of China’s domestic standard for active folate and helped drive five subsequent upgrades.

On the capital side, the company has completed multiple rounds of strategic financing, bringing well-known listed pharmaceutical companies such as Tigermed and Primus Partners into its shareholder base. This provides strong support for continued R&D and global market expansion.Looking ahead, Jinkang Hexin will continue to make technological innovation its core driver, accelerate the industrialization of Naturalization folate, and steadily advance toward becoming a global leader in active folate.

Disclaimer: This article is compiled from publicly available literature and is intended for industry discussion and reference only. It does not constitute a procurement recommendation or an efficacy commitment. Animal-study findings cannot be directly extended to efficacy claims in humans. Specific product claims must comply with applicable laws and regulations.